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ABSTRACT 
The liquisolid technique is a novel approach for delivery of drugs through the oral route. This technique is suitable for poorly soluble or water 
insoluble drugs, highly permeable drugs (BCS Class II drugs) and also for immediate or sustained release formulations. It is a novel "Powder 
Solution Technology" that involves absorption and adsorption efficiencies, making use of liquid medications, drug suspensions admixed with 
suitable carriers, coating materials and formulated into free flowing, dry looking, non-adherent and compressible powder forms. The design of 
liquisolid systems are mainly intended for enhancement of solubility, dissolution rate and bioavailability of poorly water-soluble and highly 
lipophilic drugs. Improvement in bioavailability may be due to increased surface area, increased aqueous solubility and increased the wettability of 
the drug. Liquisolid technique also has the potential to be optimized for the reduction of drug dissolution rate and thereby production of sustained 
release systems. Overall, liquisolid technique is a most promising and novel technique for enhancing the dissolution and bioavailability of poorly 
water soluble drugs and sustaining drug release from tablet matrices. The current review mainly focuses on theory and applicability of liquisolid 
compact technique towards solubility or bioavailability enhancement. Different carriers, solvents and coating materials employed are elucidated. 
Literature reports on the applicability of liquisolid compact techniques over a wide range of pharmaceutical formulations are also explicated. 
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Out of the numerous challenges in the design of pharmaceutical 
dosage forms, the most important is the solubility enhancement of 
poorly water-soluble drugs and improvement of bioavailability [1]. 
In recent years, the number of drug candidate has increased. 
However, most of these drugs are highly lipophilic and poorly 
water-soluble about 40% of the newly developed drugs and nearly 
60% of the synthesised chemical entities suffer from solubility 
issues [2, 3]. 
  
Table 1: Descriptive terms for solubility according to Indian pharmacopoeia [4] 
S. No. Descriptive terms Parts of solvent required to dissolve one part of solute (ml) 
1 Very soluble Less than 1 
2 Freely soluble More than 1 but less than 10 
3 Soluble More than 10 but less than 30 
4 Sparingly soluble More than 30 but less than 100 
5 Slightly soluble More than 100 but less than1000 
6 Very slightly soluble More than 1000 but less than 10,000 
7 Insoluble More than 10,000 
 
Those belonging to the BCS class II and IV, dissolve poorly, slowly, 
and irregularly and hence possess serious delivery challenges like 
the incomplete release of drug from the dosage form, poor 
bioavailability of drug and high inter-patient variability [5]. 
 
Table 2: Biopharmaceutical classification system [5] 
S. No. BCS class Solubility Permeability Examples 
1 I High High Metoprolol, Diltiazem, Verapamil, Propranolol, 
2 II Low High Danazol, Nifedipine, Ketoprofen, Naproxen, 
3 III High Low Atenolol, Captopril Ranitidine, Acyclovir 
4 IV Low Low Taxol, Furosemide. 
 
Techniques for solubility enhancement 
Many approaches have been developed for enhancement of solubility of 
poorly water-soluble and lipohilic drugs. Micronization technique is the 
most commonly used approach to improve drug solubility of poorly 
soluble drugs due to an increase in surface area. Other approaches, such 
as inclusion complexes, microencapsulation, and preparation of self-
nanoemulsions and solid lipid nanoparticles have also been studied for 
dissolution enhancement of poorly water-soluble drugs [2]. 
Liquisolid compact technique 
The liquisolid technique is a novel and most promising technique for 
improving the dissolution rate of poorly water-soluble drugs. In this 
technique with the use of carrier and coating materials the liquid 
form of drug converted into dry looking, non-adherent, free flowing, 
and directly compressible powder. In liquisolid system, the liquid 
portion is a drug suspension, liquid drug, or drug solution made in 
suitable non-volatile liquid vehicles [6, 7]. 
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Fig. 1: Solubility enhancement techniques [2] 
 
 
Fig. 2: Liquisolid compact formation [6, 7] 
 
 
Fig. 3: Classification of liquisolid system [7, 8] 
 
*Powdered drug solution, suspension, the liquid drug is produced 
from the conversion of drug solutions or drug suspensions, and 
formulation of liquid drugs into liquisolid systems. 
Theory of liquisolid system [2, 9-11] 
For the production of liquisolid systems amounts of powder 
excipients required is calculated by using a mathematical approach 
developed by Spireas. This approach is depends on the flowable (∅-
value) and compressible (φ-number) liquid retention potential 
introducing constants for each powder/liquid combination. 
The φ-number of a powder is defined as the maximum amount of 
non-volatile liquid the powder can retain inside its bulk while 
maintaining acceptable compatibility resulting in compacts of 
sufficient hardness during compression. It can be measured as the 
maximum crushing strength of one-gram tablet compacted at 
sufficiently high compression forces. 
The ∅-value of a powder is defined as the maximum amount of a 
given non-volatile liquid that can be retained inside its bulk while 
maintaining an acceptable flowability.  
Panda et al. 
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The liquid load factor that ensures acceptable flowability (∅Lf ) can 
be determined by:  
Lf = ∅ + φ(1 R⁄ ) 
Where, ∅ and φ are the ∅-values of the carrier and coating material, 
respectively. 
Depending on the excipient ratio (R) of the powder substrate an 
acceptably flowing and compressible liquisolid system can be 
obtained only if a maximum liquid load on the carrier material is not 
exceeded.  
R = Q q⁄  
R represents the ratio between the weights of the carrier (Q) and the 
coating (q) material present in the formulation. 
By using the following equation we can measure the quantities of 
carriers (Q0) and coating (q0
 
) materials are required to convert 
liquid formulation (W) into acceptably flowing and directly 
compressible powder.  
Q0 = W L0⁄  
q0 = Q0 R⁄  
Table 3: ∅-values and 𝝋𝝋-values of different carrier and coating materials [12] 
S. No. Powder excipients  ∅ value  𝝋𝝋 value 
Propylene glycol PEG 400 Propylene glycol PEG 400 
1 Avicel PH102 0.16 0.005 0.224 0.242 
2 Avicel PH200 0.26 0.02 0.209 0.232 
3 Cab-O-Sil M5 with Avicel PH 102 3.31 3.26 0.560 0.653 
4 Cab-O-Sil M5 with Avicel PH 200 2.56 2.44 0.712 0.717 
 
Enhanced drug release mechanism from liquisolid systems 
Three main mechanisms are involved for enhancement of drug 
release from liquisolid systems are as follows 
Increased drug surface area 
In liquisolid system the surface area of drug available for drug release 
is much greater than that of drug particles within directly compressed 
tablets because the drug present in the liquisolid system is completely 
dissolved in the liquid vehicle and present in the powder substrate still 
in a solubilized, molecularly dispersed state [9]. 
Consequently, with increasing drug content, the solubility limit also 
increases and thus, increasing the fraction of undissolved drug in the 
liquid vehicle and thus, the release rate decreases. In the liquid solid 
formulation, the release rate of the drug is directly proportional to 
the fraction of the molecularly dispersed drug (FM). Spireas defined 
FM as the ratio of the drug solubility (Sd) and the actual drug 
concentration (Cd) in the liquid vehicle [13]. 
FM = Sd Cd⁄  
Where FM = 1 Sd ≥ Cd 
 
 
Fig. 4: Increased drug surface area [13] 
 
Increased aqueous solubility of the drug  
The solubility of the drug may be increased with liquisolid system. In 
fact, the small amount of the liquid vehicle in a liquisolid compact is not 
sufficient to increase the overall solubility of the drug in the aqueous 
dissolution medium. If the small amount of liquid vehicle acts as a co-
solvent in liquisolid system this less amount of vehicle is sufficient to 
increase the aqueous solubility of the poorly water soluble drug [14]. 
 
 
Fig. 5: Increased aqueous solubility of drug [14] 
 
Increased wettability  
The non-volatile solvent present in the liquisolid system provides 
wetting of drug particles by decreasing interfacial tension between 
tablet surface and dissolution medium so the contact angle of 
liquisolid system is lower when compared to the conventional 
formulation thus improved wettability [13]. 
 
 
Fig. 6: Contact angle of conventional and liquisolid tablets [13] 
 
Requirements for preparation of liquisolid systems 
Drug candidates [15] 
Drug substance with solubilities below 0.1 mg/ml face significant 
solubilization obstacles, and often even compounds with solubilities 
below 10 mg/ml present difficulties related to solubilization during 
formulation.
 
Table 4: Drugs used in liquisolid systems [15] 
S. No. Name of the drug Use 
1 Griseofulvin Anti-fungal 
2 Lovastatin Hypertriglyceridemia 
3 Felodipine Anti-hypertension 
4 Budesonide Anti-asthmatic 
5 Aceclofenac NSAIDS 
6 Carbamazepine Anti-epileptic 
7 Nevirapine Anti-viral 
8 Praziquantel Anti-helmeted 
9 Trimethoprim Anti-biotic 
10 Clofibrate Antihyperlipidemic 
Panda et al. 




Non-volatile solvents used in the liquisolid systems should be safe, 
water-miscible, inert, not highly viscous. The carriers and coating 
materials required to prepare the liquisolid system decreases with 
increase in the solubility of the drug in a non-volatile solvent [16]. 
Carrier materials 
Carriers used in liquisolid systems should have a porous surface and 
high liquid absorption capacity. Specific surface area and liquid 
absorption capacity are the most important properties of carriers and 
these carriers incorporate large amount liquid in its structure [2, 16]. 
Coating materials 
The coating material in liquisolid system should be a material 
possessing fine (0.01–5 µm in diameter) and highly absorptive 
particles, which contribute to covering the wet carrier particles and 
displaying a dry powder by adsorbing excess amount of liquid to 
ensure good flowability of created blend [5]. 
 
Table 5: Various non-volatile solvents used in liquisolid system [6] 
S. No. Non-volatile solvent HLB value 
1 Propylene glycol 2.5 
2 Polyethylene glycol 200 monostearate 8 
3 Polyethylene glycol 400 monostearate 11.5 
4 Polysorbate 80 15 
5 Capryol™ 90 5 
 
Table 6: various types of carrier materials used in liquisolid system [2, 6] 
S. No. Carrier material Specific surface area (m2/g) 
1 Microcrystalline cellulose 1.18 
2 Lactose 0.35 
3 Sorbitol 0.37 
4 Starch  0.6 
5 Fujicalin 40 ® 
6 Neusilin 300 ® 
 
Table 7: Various types of coating materials used in liquisolid system [6] 
S. No. Coating material Composition Specific surface area(m2/g) 
1 Cab-O-Sil® Untreated fumed silica M5-P 220 
2 Syloid Amorphous silicon dioxide ® 312 
3 Aerosil® Hydrophilic fumed silica 200 200 
4 Neusilin Amorphous aluminomagnesium metasilicate ® 44-250 
 
Other additives 
The disintegration of solid dosage forms noticeably influences drug 
release, Sodium starch glycolate is most commonly used disintegrant 
in the formulation of liquisolid tablets [1]. 
Polyvinylpyrrolidone (PVP) is another promising additive, which has 
the potential to incorporate a high amount of drug into liquisolid 
systems and minimizes the overall tablet weight. 
There is another additive used in liquisolid systems–HPMC, which 
usually acts as a release retarding agent to sustain drug release from 
liquisolid tablet [8].  
Advantages of liquisolid systems [11, 15, 17] 
1. Liquisolid technique has the potential to formulate liquisolid 
tablets or capsules with pH-independent drug release pro files.  
2. Enhanced bioavailability can be obtained in liquisolid 
technique.  
3. Though the drug is in a tableted dosage form it is held in a 
solubilized liquid state, which increases drug wetting properties, 
drug dissolution rate and bioavailability.  
4. Industrial production of liquisolid tablets or capsules is 
Possible. 
5. Water insoluble drugs exhibit enhanced in vivo and in-vitro 
drug release profiles in the liquisolid system. 
6. For the formulation of the liquisolid system, less excipients are 
required when compared to conventional formulations. 
7. Increased surface area of drug exposed to dissolution medium.  
8. By using hydrophobic carriers like Eudragit® 
9. Production cost is low when compared to soft gelatin capsules. 
RL and RS 
formulation of sustained release liquisolid tablets are possible.  
10. Liquisolid approach omits the process approaches like 
nanonisation, micronization techniques. 
Disadvantages of liquisolid systems [18-20] 
1. Liquisolid systems require high solubility of drug in non-
volatile solvents. 
2. High levels of carrier material and coating materials should be 
required in order to achieve acceptable flowability and 
compactibility for liquisolid powder formulation.  
Liquisolid system is the problematic formulation of a high dose of 
poorly water soluble drugs (e. g., carbamazepine, budesonide). 
Advantages of liquisolid systems [11, 15, 17] 
11. Liquisolid technique has the potential to formulate liquisolid 
tablets or capsules with pH-independent drug release pro files.  
12. Enhanced bioavailability can be obtained in liquisolid technique.  
13. Though the drug is in a tableted dosage form it is held in a 
solubilized liquid state, which increases drug wetting properties, 
drug dissolution rate and bioavailability.  
14. Industrial production of liquisolid tablets or capsules is 
Possible. 
15. Water insoluble drugs exhibit enhanced in vivo and in-vitro 
drug release profiles in liquisolid system. 
Panda et al. 
Int J App Pharm, Vol 9, Issue 3, 2017, 8-14 
 
12 
16. For the formulation of liquisolid system less excipients are 
required when compared to conventional formulations. 
17. Increased surface area of drug exposed to dissolution medium.  
18. By using hydrophobic carriers like Eudragit®
19. Production cost is low when compared to soft gelatin capsules. 
RL and RS 
formulation of sustained release liquisolid tablets are possible.  
20. Liquisolid approach omits the process approaches like 
nanonisation, micronization techniques. 
Disadvantages of liquisolid systems [18-20] 
3. Liquisolid systems require high solubility of the drug in non-
volatile solvents. 
4. High levels of carrier material and coating materials should be 
required in order to achieve acceptable flowability and compatibility 
for liquisolid powder formulation.  
5. Liquisolid system is the problematic formulation of a high dose 
of poorly water soluble drugs (e. g., carbamazepine, budesonide). 
Applications of liquisolid systems [21-25] 
1. Drug photostability in solid dosage forms is improved by 
liquisolid technique. 
2. The rapid and prolonged release of drugs is obtained in 
liquisolid formulations. 
3. The liquisolid technique is most efficiently used for water-
insoluble solid drugs or liquid lipophilic drugs. 
4. Liquisolid technique minimizes effect of pH variation on drug 
release. 
Drug solubility, dissolution rate is enhanced in liquisolid technique. 
Recent reports on liquisolid technique 
Mustafa E et al. (2017) had designed orodispersible tablets of 
zolmitriptan by using liquisolid technique. Orodispersible tablets 
were prepared by using propylene glycol, avicel PH-102 and 
aerosil 200 as a non-volatile solvent, carrier material and coating 
material respectively and various types of super disintegrating 
agents such as croscarmellose sodium, sodium starch glycolate, 
and crospovidone to facilitate faster disintegration of the liquisolid 
compact.  
The overall results showed that among the three super-
disintegrants, crospovidone was the best super disintegrant 
showing the shortest disintegration time while loading factor of 
0.125 was the best in the preparing of zolmitriptan liquidsolid 
orodispersible tablets [26]. 
 
Procedure for designing of liquisolid formulation 
 
 
Fig. 7: General preparation procedure of liquisolid formulation [2] 
  
Padmapreetha J et al. (2016) had formulated liquisolid compact to 
enhance the dissolution rate of leflunomide by using kolliphor EL, 
avicel PH 102, aerosol, and sodium starch glycolate as a non-volatile 
solvent, carrier, coating material and super disintegrant respectively. 
The results showed that during the first 10 min (Q10%
Mowafaq MG et al. (2015) had prepared liquisolid compact for 
solubility enhancement of tenoxicam using tween 80 as a non-
volatile liquid, avicel PH102 as a carrier, and aerosil 200 as a coating 
material. Liquisolid formulations containing various drug 
concentrations in liquid medication ranging from 10% to 35% w/w 
were prepared. Liquisolid formulations showed greater drug release 
rates than conventional and marketed tablets due to increasing 
surface area of the drug and wetting properties [28].  
) the optimized 
formulation released 73.39% of its content compared to 18.94 % of 
the conventional formulation. In conclusion, leflunomide dissolution 
rate can be enhancing to a greater extent by liquisolid technique [27]. 
Hitesh J et al. (2014) had compared liquisolid and inclusion 
complexation techniques for dissolution rate enhancement of 
valsartan. This study was designed for screening of suitable non-
volatile liquid solvent for the preparation of liquisolid compact such 
as tween 80, polyethyleneglycol 400 and propylene glycol by using 
the mathematical equation. The study was also aimed for 
enhancement of dissolution rate and comparison of liquisolid 
technique with inclusion complex of β-cyclodextrin. The liquisolid 
formulation showed highest dissolution rate compared with directly 
compressed tablet, pure drug, and formulation prepared by 
complexation technique [29]. 
Yesubabu B et al. (2014) had formulated fast disintegrating tablets 
of lamotrigine using different super disintegrating agents such as 
crospovidone, sodium starch glycolate. Various batches of liquisolid 
tablets were prepared. Formulations consisting of sodium starch 
glycolate were found to be fulfilling all the parameters satisfactorily 
Panda et al. 
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when compared with crospovidone. In-vitro, drug release studies 
showed that within 30 min almost 90% of the drug was released 
from all the formulations confirming enhancement of drug 
dissolution by liquisolid technique [30]. 
Ali N et al. (2008) had designed sustained release liquisolid compact 
of propranolol hydrochloride by dispersing the drug in polysorbate 
80 as the non-volatile solvent. A binary mixture of Eudragit RL or RS 
were used as the carrier. Silica was added to the liquid medium as 
the coating material with continuous mixing in a mortar. Then the 
final mixture was compressed using the tablet punching machine. 
 The effect of drug concentration, loading factor, thermal treating 
and aging on drug release profiles of propranolol HCl from liquisolid 
compacts was investigated at two different pH values such as 1.2 
and 6.8. In conclusion, propranolol HCl tablets prepared by liquisolid 
system showed greater retardation properties than conventional 
matrix tablets [31]. 
 
Table 8: Literature reports on formulations of liquisolid compact 
S. 
No. 




1 Budesonide PEG 400 Avicel PH 102 Aerosil 200 19 
2 Carvedilol PEG 400 Avicel PH 101 Aerosil 200 32 
3 Candesartan cilexetil Tween 80 Avicel PH 102 Aerosil 200 33 
4 Efavirenz Propylene glycol Avicel PH 102 Aerosil 200 34 
5 Felodipine PEG 400 Avicel PH 102 Aerosil 200 35 
6 Gliclazide Acrysol EL 135 Avicel PH 102 and Neusilin Aerosil 200 36 
7 Glyburide PEG 400 Avicel PH 101 and 102 Aerosil 200 37 
8 Hydrochlorothiazide PEG 400+Water+Tween 60 Microcrystalline cellulose Colloidal silicon 
dioxide 
38 
9 Ibuprofen PEG 400 Avicel PH 101 Aerosil 39 
10 Indomethacin Glycerin Micro crystalline cellulose Silica 40 
11 Naproxen PEG 400, 200, 600, PG, Glycerin, Tween 80, 
Cremophor EL and Poloxamer 181 
Microcrystalline cellulose and 
Dicalcium phosphate 
Colloidal silica 12 
12 Nateglinide PEG 400 Avicel PH 102 Aerosil 200 41 
13 Nifedipine PEG 400, PG and 
Tween 80 
Avicel PH 102 Silica gel 
powder 
42 





Tween 80 Avicel PH 102 Aerosil 44 
16 Tramadol hydrochloride Propylene glycol Avicel PH 102 Aerosil 200 45 
 
CONCLUSION 
Enhancement of the solubility and dissolution rate of poorly water-
soluble drugs is still a major challenge for pharmaceutical scientists. 
At the same time sustaining the drug release from dosage forms 
helps in a better and proper utilization of the drug. Both of these 
applications are major requisites for enhancement of drug 
bioavailability. Finally, from this review, it can be concluded that, 
among the various techniques involved for the drug bioavailability 
enhancement, liquisolid technology is one of the most promising 
approaches. It is found to be a multipotential and promising 
technology for dosage form development, because of the process 
simplicity, low economic inputs during production and possible 
industrial feasibility due to the good flow and compaction 
characteristics of liquisolid formulations.  
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